VERU INC. Current Income Tax Expense (Benefit)
VERU INC. (VERU) reported Current Income Tax Expense (Benefit) of $357.92 thousand for the 12-month period ending 2024-09-30, per its 10-K filed 2024-12-16.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentIncomeTaxExpenseBenefit · last filed 2024-12-16
- VERU INC. current income tax expense (benefit) for fiscal 2024 was $357.92K, a 18.24% increase from fiscal 2023.
- VERU INC. current income tax expense (benefit) for fiscal 2023 was $302.71K, a 88.97% increase from fiscal 2022.
- VERU INC. current income tax expense (benefit) for fiscal 2022 was $160.19K, a 63.59% decline from fiscal 2021.
- VERU INC. current income tax expense (benefit) for fiscal 2021 was $439.91K, a 149.14% increase from fiscal 2020.
| Period end | Current Income Tax Expense (Benefit) 12 month | Current Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|
| 2024-09-30 | $357.92K 10-K · filed 2024-12-16 | |
| 2023-09-30 | $302.71K 10-K · filed 2024-12-16 | |
| 2022-09-30 | $160.19K 10-K/A · filed 2024-04-01 | |
| 2021-09-30 | $439.91K 10-K · filed 2022-12-05 | |
| 2020-09-30 | $176.57K 10-K · filed 2021-12-02 | |
| 2019-09-30 | $134.13K 10-K · filed 2020-12-10 | |
| 2018-09-30 | $235.95K 10-K · filed 2019-12-12 | |
| 2017-09-30 | $264.63K 10-K · filed 2018-12-13 | |
| 2016-09-30 | $414.37K 10-K · filed 2018-01-02 | |
| 2015-09-30 | $415.26K 10-K · filed 2018-01-02 | |
| 2014-09-30 | $511.80K 10-K · filed 2016-12-12 | |
| 2013-09-30 | $850.32K 10-K · filed 2015-12-02 | |
| 2012-09-30 | $386.63K 10-K · filed 2014-12-02 | -$4.51M 10-K · filed 2012-12-04 |
| 2011-09-30 | $296.97K 10-K · filed 2013-12-03 | -$2.17M 10-K · filed 2012-12-04 |
| 2010-09-30 | -$2.51M 10-K · filed 2012-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |